Xiaohong Peng

Xiaohong Peng


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2024 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
NLNa Luo
Na Luo
WZWenjun Zhu
Wenjun Zhu
XLXiaoyu Li
Xiaoyu Li
MFMin Fu
Min Fu
YZYuanyuan Zhang
Yuanyuan Zhang
XPXiaohong Peng
Xiaohong Peng
Background: Radiation-induced brain injury (RBI) represents a major challenge for cancer patients undergoing cranial radiotherapy. However, the molecular mechanisms and therapeutic strategies of RBI remain inconclusive. With the continuous exploration of the mechanisms of RBI, an increasing number of studies have implicated cerebrovascular dysfunction as a key factor in RBI-related cognitive impairment. As pericytes are a component of the neurovascular unit, there is still a lack of understanding in current research about the specific role and function of pericytes in RBI. Methods: We constructed a mouse model of RBI-associated cognitive dysfunction in vivo and an in vitro radiation-induced pericyte model to explore the effects of senescent pericytes on the blood-brain barrier (BBB) and normal central nervous system cells, even glioma cells. To further clarify the effects of pericyte autophagy on senescence, molecular mechanisms were explored at the animal and cellular levels. Finally, we validated the clearance of pericyte senescence by using a senolytic drug and all-trans retinoic acid to investigate the role of radiation-induced pericyte senescence. Results: Our findings indicated that radiation-induced pericyte senescence plays a key role in BBB dysfunction, leading to RBI and subsequent cognitive decline. Strikingly, pericyte senescence also contributed to the growth and invasion of glioma cells. We further demonstrated that defective autophagy in pericytes is a vital regulatory mechanism for pericyte senescence. Moreover, autophagy activated by rapamycin could reverse pericyte senescence. Notably, the elimination of senescent cells by senolytic drugs significantly mitigated radiation-induced cognitive dysfunction. Conclusions: Our results demonstrated that pericyte senescence may be a promising therapeutic target for RBI and glioma progression.

25 June 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
QZQiang Zhang
Qiang Zhang
WZWan Zhang
Wan Zhang
XYXinya Yuan
Xinya Yuan
XPXiaohong Peng
Xiaohong Peng
GHGuangyuan Hu
Guangyuan Hu
With the global trend of population aging becoming increasingly pronounced, the incidence of central nervous system (CNS) disorders continues to rise, posing a significant challenge to public health systems worldwide. Currently, many CNS disorders lack effective treatments, prompting researchers to investigate the therapeutic potential of natural compounds. Urolithin A (UA), a gut microbiota-derived metabolite of ellagitannins and ellagic acid, can cross the blood–brain barrier and exhibits a favorable safety profile. This review summarizes the biosynthesis, pharmacokinetic profile, and key biological effects of UA, including its promotion of mitophagy and mitochondrial homeostasis, as well as its anti-inflammatory, antioxidant, anti-senescence, and anti-apoptotic properties. We comprehensively summarize the preclinical evidence demonstrating UA’s therapeutic potential in CNS disorders, such as Alzheimer’s disease, Parkinson’s disease, and stroke. Recent clinical trials involving UA are presented, followed by a thorough analysis of the challenges associated with translating UA-based interventions into clinical practice for CNS disorders. This work aims to support the development of UA-based therapies to improve patient outcomes and address the growing global burden of CNS disorders.

15 September 2023 in Apoptosis
Verified
Journal Article
Open access
PDF file
WZWenjun Zhu
Wenjun Zhu
ZCZiqi Chen
Ziqi Chen
MFMin Fu
Min Fu
QLQianxia Li
Qianxia Li
XCXin Chen
Xin Chen
GHGuangyuan Hu
Guangyuan Hu
Cuprotosis, an emerging mode of cell death, has recently caught the attention of researchers worldwide. However, its impact on low-grade glioma (LGG) patients has not been fully explored. To gain a deeper insight into the relationship between cuprotosis and LGG patients’ prognosis, we conducted this study in which LGG patients were divided into two clusters based on the expression of 18 cuprotosis-related genes. We found that LGG patients in cluster A had better prognosis than those in cluster B. The two clusters also differed in terms of immune cell infiltration and biological functions. Moreover, we identified differentially expressed genes (DEGs) between the two clusters and developed a cuprotosis-related prognostic signature through the least absolute shrinkage and selection operator (LASSO) analysis in the TCGA training cohort. This signature divided LGG patients into high- and low-risk groups, with the high-risk group having significantly shorter overall survival (OS) time than the low-risk group. Its predictive reliability for prognosis in LGG patients was confirmed by the TCGA internal validation cohort, CGGA325 cohort and CGGA693 cohort. Additionally, a nomogram was used to predict the 1-, 3-, and 5-year OS rates of each patient. The analysis of immune checkpoints and tumor mutation burden (TMB) has revealed that individuals belonging to high-risk groups have a greater chance of benefiting from immunotherapy. Functional experiments confirmed that interfering with the signature gene TNFRSF11B inhibited LGG cell proliferation and migration. Overall, this study shed light on the importance of cuprotosis in LGG patient prognosis. The cuprotosis-related prognostic signature is a reliable predictor for patient outcomes and immunotherapeutic response and can help to develop new therapies for LGG.

8 November 2024 in JCI Insight
Verified
Journal Article
Open access
MFMin Fu
Min Fu
YZYiling Zhang
Yiling Zhang
BPBi Peng
Bi Peng
NLNa Luo
Na Luo
YZYuanyuan Zhang
Yuanyuan Zhang
XPXiaohong Peng
Xiaohong Peng
Radiotherapy (RT) remains a primary treatment modality for glioblastoma (GBM), but it induces cellular senescence and is strongly implicated in GBM progression and RT-related injury. Recently, eliminating senescent cells has emerged as a promising strategy for treating cancer and for mitigating radiation-induced brain injury (RBI). Here, we investigated the impact of all- trans retinoic acid (RA) on radiation-induced senescence. The findings of this study revealed that RA effectively eliminated astrocytes, which are particularly prone to senescence after radiation, and that the removal of senescence-associated secretory phenotype factor–producing astrocytes inhibited GBM cell proliferation in vitro. Moreover, RA-mediated clearance of senescent cells improved survival in GBM-bearing mice and alleviated radiation-induced cognitive impairment. Through RNA sequencing, we found that the AKT/mTOR/PPARγ/Plin4 signaling pathway is involved in RA-mediated clearance of senescent cells. In summary, these results suggest that RA could be a potential senolytic drug for preventing GBM progression and improving RBI.

20 July 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
NLNa Luo
Na Luo
XSXizi Sun
Xizi Sun
SMShengling Ma
Shengling Ma
XLXiaoyu Li
Xiaoyu Li
WZWenjun Zhu
Wenjun Zhu
GHGuangyuan Hu
Guangyuan Hu
Background: Accumulating evidence shows that m6A regulates oncogene and tumor suppressor gene expression, thus playing a dual role in cancer. Likewise, there is a close relationship between the immune system and tumor development and progression. However, for glioblastoma, m6A-associated immunological markers remain to be identified.Methods: We obtained gene expression, mutation, and clinical data on glioblastoma from The Cancer Genome Atlas and Chinese Glioma Genome Atlas databases. Next, we performed univariate COX–least absolute shrinkage and selection operator (LASSO)–multivariate COX regression analyses to establish a prognostic gene signature and develop a corresponding dynamic nomogram application. We then carried out a clustering analysis twice to categorize all samples according to their m6A-regulating and m6A-associated immune gene expression levels (high, medium, and low) and calculated their m6A score. Finally, we performed quantitative reverse transcription-polymerase chain reaction, cell counting kit-8, cell stemness detection, cell migration, and apoptosis detection in vitro assays to determine the biological role of CD81 in glioblastoma cells.Results: Our glioblastoma risk score model had extremely high prediction efficacy, with the area under the receiver operating characteristic curve reaching 0.9. The web version of the dynamic nomogram application allows rapid and accurate calculation of patients’ survival odds. Survival curves and Sankey diagrams indicated that the high-m6A score group corresponded to the groups expressing medium and low m6A-regulating gene levels and high m6A-associated prognostic immune gene levels. Moreover, these groups displayed lower survival rates and higher immune infiltration. Based on the gene set enrichment analysis, the pathophysiological mechanism may be related to the activation of the immunosuppressive function and related signaling pathways. Moreover, the risk score model allowed us to perform immunotherapy benefit assessment. Finally, silencing CD81 in vitro significantly suppressed proliferation, stemness, and migration and facilitated apoptosis in glioblastoma cells.Conclusion: We developed an accurate and efficient prognostic model. Furthermore, the correlation analysis of different stratification methods with tumor microenvironment provided a basis for further pathophysiological mechanism exploration. Finally, CD81 may serve as a diagnostic and prognostic biomarker in glioblastoma.

6 March 2024 in Research Square
Verified
Preprint
Open access
PDF file
YZYiling Zhang
Yiling Zhang
NLNa Luo
Na Luo
XLXiaoyu Li
Xiaoyu Li
CZChuanfei Zeng
Chuanfei Zeng
WZWenjun Zhu
Wenjun Zhu
GHGuangyuan Hu
Guangyuan Hu
Low-grade glioma (LGG) is a lower malignancy and slower-growing primary tumor of the nervous system. Methylation of N6-methyl adenosine (m6A) has important roles in the growth of tumors and cellular biological processes. The immune system is involved in tumourigenesis and development and plays a certain role in tumor therapy and resistance to drugs. There have been no in-depth studies on m6A-related immune markers in LGG. We obtained gene mutation data, gene expression, and related clinical information of LGG patients from the Chinese Glioma Genome Atlas (CGGA) database and the Cancer Genome Atlas (TCGA). Then, the prognostic model was calculated using multivariate Cox, LASSO, and univariate Cox analyses. A dynamic nomograph online app was also developed based on this model. In addition, for the screened model genes, we performed correlation analyses in the clinical staging, immunological subtype, and microenvironmental aspects. Finally, we determined the biological role of FBXO4 in glioma cells by quantitative reverse transcription-polymerase chain reaction, cell proliferation assay, and cell migration assay. Our prognostic models can accurately and efficiently help investigators analyze the prognosis of LGG patients. In addition, the correlation analysis between m6Ascore and tumor microenvironment can provide a basis for further exploration.